Atropos Health Secures $33 Million in Series B Funding to Transform Patient Care
Atropos Health, an innovative healthcare technology company dedicated to delivering personalized real-world evidence, has successfully raised $33 million in its Series B funding round. This significant investment includes contributions from industry leaders McKesson, Merck, and Cencora Ventures, underscoring the strong interest in Atropos’ mission to enhance patient care decisions with automated, high-quality evidence.
Expanding Operations and Key Initiatives
Based in Silicon Valley, Atropos plans to utilize the new funding to broaden its operations and intensify focus on key initiatives. These include expanding into life sciences, strengthening partnerships in value-based and oncology care, and enhancing its evidence network by collaborating with more data partners.
“We’re on a mission to bring personalized evidence for care to everyone in the world, and this funding is a crucial step in that journey,” stated Brigham Hyde, PhD, CEO and co-founder of Atropos Health. “We aim to build on our traction in life sciences and deepen our collaboration with channel partners, particularly in value-based and specialty care oncology.”
AI-Powered Clinical Evidence Generation
Atropos’ flagship technology, Geneva OS, employs AI and automation to rapidly generate clinical-grade evidence from real-world data. This platform, developed over nearly a decade of research at Stanford, powers applications like ChatRWD, Atropos’ generative AI assistant. Clinicians, researchers, and healthcare stakeholders can quickly access reliable clinical evidence tailored to specific patient populations, addressing a critical gap in today’s healthcare landscape.
Hyde highlighted, “Currently, only about 14% of daily medical decisions are supported by high-quality evidence. This shocking statistic stems from our reliance on clinical trial data, which is limited. We aim to fill this evidence gap by utilizing high-quality data analyzed accurately and efficiently.”
Addressing the Evidence Gap for Improved Patient Outcomes
Atropos is committed to closing this “evidence gap” by providing clinicians with personalized evidence relevant to their patients. “Diverse patient populations often present with different comorbidities and histories,” Hyde noted. “We need clear evidence for these subpopulations—data that may not yet be reflected in literature or clinical trials. Instead of treating every heart failure patient the same, let’s tailor treatment based on evidence that yields better outcomes and controls costs.”
Streamlining Pharmaceutical R&D Through Real-World Evidence
Atropos’ technology also extends its utility beyond clinical decision-making, partnering with pharmaceutical companies like Janssen to enhance drug development processes. This includes generating evidence for clinical trial design, patient recruitment, and even simulating trial outcomes.
“What if we could gather reliable evidence to accelerate trial design?” Hyde asked. “What if we could optimize recruitment using enhanced data, leading to more successful trials? Our goal is to reduce the cycle time in R&D while minimizing the risks associated with clinical trials.”
Building Trust in Generative AI for Healthcare
Atropos’ Series B funding aligns with the growing interest in the application of generative AI across specialized sectors, particularly healthcare. Hyde emphasizes the necessity of establishing trust through methodological rigor and transparency.
“While there’s considerable excitement around large language models, we’re cautious due to concerns about hallucination rates,” he explained. “Geneva OS guarantees clinical-grade quality, transparency, and a decade of research backing its processes, ensuring users can trust the outputs.”
With a robust funding foundation and influential strategic partners, Atropos is poised to realize its vision of delivering personalized, automated clinical evidence globally. Hyde emphasizes, “Evidence is the currency of value in healthcare. By providing more personalized evidence, we empower doctors to make better decisions. Our mission is to ensure that all patients and providers access high-quality, personalized evidence for informed decision-making.”
Ranking
